EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of piperacillin–tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing Enterobacteriaceae

Wei Zhang, Chun-Yu Yan, Shu-Rui Li, Ting-Ting Fan, Shan-Shan Cao, Bin Cui, Meng-Ying Li, Bo-Yuan Fan, Bo Ji, Li Wang, Fei Cui, Jia Cui und 3 weitere

Frontiers in Cellular and Infection Microbiology · 2023

DOI: 10.3389/fcimb.2023.1093842 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Wei Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Urinary Tract Infections, Pyelonephritis, Enterobacteriaceae Infections. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae pose a huge threat to human health, especially in the context of complicated urinary tract infections (cUTIs). Carbapenems and piperacillin–tazobactam (PTZ) are two antimicrobial agents commonly used to treat cUTIs.

Methods

A monocentric retrospective cohort study focused on the treatment of cUTIs in adults was conducted from January 2019 to November 2021. Patients with a positive urine culture strain yielding ≥ 103 colony-forming units per milliliter (CFU/mL), and sensitive to PTZ and carbapenems, were included. The primary endpoint was clinical success after antibiotic therapy. The secondary endpoint included rehospitalization and 90-day recurrence of cUTIs caused by ESBL-producing Enterobacteriaceae.

Results

Of the 195 patients included in this study, 110 were treated with PTZ while 85 were administered meropenem. The rate of clinical cure was similar between the PTZ and meropenem groups (80% vs. 78.8%, p = 0.84). However, the PTZ group had a lower duration of total antibiotic use (6 vs. 9; p < 0.01), lower duration of effective antibiotic therapy (6 vs. 8; p < 0.01), and lower duration of hospitalization (16 vs. 22; p < 0.01).

Discussion

In terms of adverse events, the safety of PTZ was higher than that of meropenem in the treatment of cUTIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Tract InfectionsPyelonephritisEnterobacteriaceae InfectionsAdultHumansMeropenemPiperacillinRetrospective Studiesbeta-Lactamase InhibitorsPenicillanic AcidAnti-Bacterial AgentsPiperacillin, Tazobactam Drug CombinationEnterobacteriaceaeCarbapenemsbeta-Lactamases

Stichwörter der Autor:innen

ESBLantibiotic treatmentcomplicated urinary tract infectionsmeropenempiperacillin-tazobactam

Substanzen

MeropenemPiperacillinbeta-Lactamase InhibitorsPenicillanic AcidAnti-Bacterial AgentsPiperacillin, Tazobactam Drug CombinationCarbapenemsbeta-Lactamases

Autor:innen und Institutionen

  • Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
  • Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, United Kingdom.
  • Department of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Department of Endocrinology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
  • Department of Cardiology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, W., Yan, C. Y., Li, S. R., Fan, T. T., Cao, S. S., Cui, B., Li, M. Y., Fan, B. Y., Ji, B., Wang, L., Cui, F., Cui, J., Wang, L., Guan, Y., & Wang, J. W. (2023). Efficacy and safety of piperacillin–tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing Enterobacteriaceae. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1093842

Vancouver

Zhang W, Yan CY, Li SR, Fan TT, Cao SS, Cui B, et al. Efficacy and safety of piperacillin–tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing Enterobacteriaceae. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1093842

BibTeX
@article{Zhang2023,
  author = {Zhang, Wei and Yan, Chun-Yu and Li, Shu-Rui and Fan, Ting-Ting and Cao, Shan-Shan and Cui, Bin and Li, Meng-Ying and Fan, Bo-Yuan and Ji, Bo and Wang, Li and Cui, Fei and Cui, Jia and Wang, Lei and Guan, Yue and Wang, Jing-Wen},
  title = {Efficacy and safety of piperacillin–tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing Enterobacteriaceae},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2023},
  doi = {10.3389/fcimb.2023.1093842}
}
Kostenlos starten →